Hannah Clarke

“NSD2 is a cancer specific collaborator of the androgen receptor that essentially rewires its activity to support prostate cancer development," says Abhijit Parolia, PhD,

The ZIRCON trial reported high accuracy of TLX250-CDx in detecting and characterizing ccRCC in patients with indeterminate renal masses.

“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.

Piflufolastat (18F) is being produced at 2 Curium facilities in Madrid and 1 in Sevilla.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.

“Our study reveals potential differences in tolerance and effectiveness of AR inhibitors in practice, which can help clinicians and patients with treatment decisions," says Daniel J. George, MD.

“We saw in the survey that men are concerned with how the health decisions they make now will affect them in the future,” says Petar Bajic, MD.

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

Olaparib plus abiraterone and prednisone or prednisolone was granted FDA approval in May 2023 for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC.

Patients who had mutations in the ERCC2, ATM, or RB1 genes were more than 5 times more likely to achieve a pathologic complete response following cisplatin-based chemotherapy.

Treatment with an ARPI extended overall survival (OS), with a median OS of 38.7 months in the ARPI arm vs 21.7 months in the taxane arm and 21.8 months in the physician’s choice of treatment arm.

Data indicated that the test preferentially detected high-grade, clinically significant prostate cancer, with 93% of detected cancers being GG3-5 and 67% being stage 3 or 4.

In total, 8 of 40 patients who underwent ultrasonic propulsion experienced relapse, compared with 21 of 42 patients who underwent observation.

Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.

The approval is based on findings from the first interim analysis of the phase 3 EV-302 trial.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

The phase 3 trial will assess the anti-tumor activity of 9MW2821 plus toripalimab vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

"Generative AI technologies may play a valuable role in providing prompt, accurate responses to routine patient questions––potentially alleviating patients' concerns while freeing up clinic time and resources to address other complex tasks," says Michael Scott, MD.

In total, the trial plans to enroll 7 patients with PH1 through a single center in China.

The approval is supported by data from cohort 1 of the phase 3 THOR trial.

The approval is supported by findings from the phase 3 EV-302 trial.

“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.

The fast track designation for 64Cu-SAR-bisPSMA is supported by findings from Clarity’s ongoing clinical program for the imaging agent.

Any stone fragmentation was achieved in 88% of patients.

A full market release of the HYDROS System is expected within the current quarter.